Rates of CR and CRi (A) and rates of MRD negativity (B) reported in clinical trials are shown by genetic subgroup or MRD technology. The cited clinical trials are listed in Table 1. Data on mutated NPM1 and CBF MRD are based on qPCR assessment. Data on FLT3-ITD are based on NGS. MFC-MRD assessment includes studies of intermediate-risk AML with or without FLT3-ITD or mutated NPM1. CBF, core-binding factor; mut, mutated.